Literature DB >> 36112166

[56/m-Dysphagia and loss of weight : Preparation for the medical specialist examination: part 11].

Karl Knipper1, Thomas Schmidt1, Christiane J Bruns2.   

Abstract

Entities:  

Year:  2022        PMID: 36112166     DOI: 10.1007/s00104-022-01720-w

Source DB:  PubMed          Journal:  Chirurgie (Heidelb)        ISSN: 2731-6971


× No keyword cloud information.
  4 in total

1.  International Consensus on Standardization of Data Collection for Complications Associated With Esophagectomy: Esophagectomy Complications Consensus Group (ECCG).

Authors:  Donald E Low; Derek Alderson; Ivan Cecconello; Andrew C Chang; Gail E Darling; Xavier Benoit DʼJourno; S Michael Griffin; Arnulf H Hölscher; Wayne L Hofstetter; Blair A Jobe; Yuko Kitagawa; John C Kucharczuk; Simon Ying Kit Law; Toni E Lerut; Nick Maynard; Manuel Pera; Jeffrey H Peters; C S Pramesh; John V Reynolds; B Mark Smithers; J Jan B van Lanschot
Journal:  Ann Surg       Date:  2015-08       Impact factor: 12.969

2.  Propensity score analysis of oesophageal cancer treatment with surgery or definitive chemoradiotherapy.

Authors:  A Karran; P Blake; D Chan; T D Reid; I L Davies; M Kelly; S A Roberts; T Crosby; W G Lewis
Journal:  Br J Surg       Date:  2014-02-24       Impact factor: 6.939

3.  Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer.

Authors:  Ronan J Kelly; Jaffer A Ajani; Jaroslaw Kuzdzal; Thomas Zander; Eric Van Cutsem; Guillaume Piessen; Guillermo Mendez; Josephine Feliciano; Satoru Motoyama; Astrid Lièvre; Hope Uronis; Elena Elimova; Cecile Grootscholten; Karen Geboes; Syed Zafar; Stephanie Snow; Andrew H Ko; Kynan Feeney; Michael Schenker; Piotr Kocon; Jenny Zhang; Lili Zhu; Ming Lei; Prianka Singh; Kaoru Kondo; James M Cleary; Markus Moehler
Journal:  N Engl J Med       Date:  2021-04-01       Impact factor: 91.245

4.  Ten-Year Outcome of Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer: The Randomized Controlled CROSS Trial.

Authors:  Ben M Eyck; J Jan B van Lanschot; Maarten C C M Hulshof; Berend J van der Wilk; Joel Shapiro; Pieter van Hagen; Mark I van Berge Henegouwen; Bas P L Wijnhoven; Hanneke W M van Laarhoven; Grard A P Nieuwenhuijzen; Geke A P Hospers; Johannes J Bonenkamp; Miguel A Cuesta; Reinoud J B Blaisse; Olivier R Busch; Geert-Jan M Creemers; Cornelis J A Punt; John Th M Plukker; Henk M W Verheul; Ernst J Spillenaar Bilgen; Maurice J C van der Sangen; Tom Rozema; Fiebo J W Ten Kate; Jannet C Beukema; Anna H M Piet; Caroline M van Rij; Janny G Reinders; Hugo W Tilanus; Ewout W Steyerberg; Ate van der Gaast
Journal:  J Clin Oncol       Date:  2021-04-23       Impact factor: 44.544

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.